keyword
MENU ▼
Read by QxMD icon Read
search

Second lung cancer

keyword
https://www.readbyqxmd.com/read/29053106/issues-in-quantification-of-registered-respiratory-gated-pet-ct-in-the-lung
#1
Vesna Cuplov, Beverley Fiona Holman, Jamie R McClelland, Marc Modat, Brian F Hutton, Kris Thielemans
PET/CT quantification of lung tissue is limited by several difficulties: the lung density and local volume changes during respiration, the anatomical mismatch between PET and CT and the relative contributions of tissue, air and blood to the PET signal (the tissue fraction effect). Air Fraction Correction (AFC) has been shown to improve PET image quantification in the lungs. Methods to correct for the movement and anatomical mismatch involve respiratory gating and image registration techniques. While conventional registration methods only account for spatial mismatch, the Jacobian determinant of the deformable registration transformation field can be used to estimate local volume changes and could therefore potentially be used to correct (i...
October 20, 2017: Physics in Medicine and Biology
https://www.readbyqxmd.com/read/29050315/the-activation-of-src-family-kinases-and-focal-adhesion-kinase-with-the-loss-of-the-amplified-mutated-egfr-gene-contributes-to-the-resistance-to-afatinib-erlotinib-and-osimertinib-in-human-lung-cancer-cells
#2
Yuichi Murakami, Kahori Sonoda, Hideyuki Abe, Kosuke Watari, Daiki Kusakabe, Koichi Azuma, Akihiko Kawahara, Jun Akiba, Chitose Oneyama, Jonathan A Pachter, Kazuko Sakai, Kazuto Nishio, Michihiko Kuwano, Mayumi Ono
Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are improving the treatment of patients with non-small cell lung cancer. Here we established two sublines (BR1-8 and BR2-3) resistant to a second-generation inhibitor, afatinib, from the human lung cancer cell line HCC827 that harbors a mutation that activates the tyrosine kinase activity of EGFR. These afatinib-resistant sublines were resistant to first-generation EGFR-TKIs, gefitinib and erlotinib, and a third-generation EGFR-TKI, osimertinib...
September 19, 2017: Oncotarget
https://www.readbyqxmd.com/read/29049199/paclitaxel-as-third-line-chemotherapy-for-small-cell-lung-cancer-failing-both-etoposide-and-camptothecin-based-chemotherapy
#3
Se Hyun Kim, Mi-Jung Kim, Yu Jung Kim, Hyun Chang, Jin Won Kim, Jeong-Ok Lee, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong Seok Lee
Paclitaxel has been shown to have clinical activity in the treatment of small cell lung cancer (SCLC). However, its role as third-line chemotherapy for SCLC after both etoposide- and camptothecin-based regimens has not been clarified.All patients with refractory SCLC who were treated with paclitaxel-based regimen as third-line chemotherapy between 2005 and 2011 in Seoul National University Bundang Hospital were reviewed retrospectively. Forty patients previously treated with both etoposide- and camptothecin-based chemotherapy were included...
October 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/29048620/dna-methylation-and-histone-modifications-as-epigenetic-regulation-in-prostate-cancer-review
#4
Maria Nowacka-Zawisza, Ewelina Wiśnik
Prostate cancer is the second most commonly diagnosed cancer in men in Poland after lung cancer and the third leading cause of cancer-related mortality after lung and colon cancer. The etiology of most cases of prostate cancer are not fully known, and therefore it is essential to search for the molecular basis of prostate cancer and markers for the early diagnosis of this type of cancer. Epigenetics deals with changes in gene expression that are not determined by changes in the DNA sequence. Epigenetic changes refer to changes in the structure of DNA, which are the result of DNA modification after replication and/or post-translational modification of proteins associated with DNA...
September 20, 2017: Oncology Reports
https://www.readbyqxmd.com/read/29046751/case-series-of-multiple-primary-cancers-in-single-individuals-diagnostic-and-therapeutic-dilemmas
#5
Faizan Malik, Naveed Ali, Jibran Durrani, Syed Imran Mustafa, Crystal Denlinger
Background and Objectives: Cancer recurrence represents treatment failure; the development of new primary tumors is suggestive of persistent exposure to etiological risk factors or genetic predisposition due to mutations in multiple cell lines. Case presentation/Design/Methods: The first case is a 65-years-old Caucasian male who presented with esophageal and lung cancer diagnosed synchronously. Smoking was the common risk factor for both cancers, underscoring field cancerization. The diagnosis and management was a challenge and different from either cancer presenting alone...
October 2017: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/29046702/in-vivo-validation-of-metastasis-regulating-microrna-766-in-human-triple-negative-breast-cancer-cells
#6
Keunhee Oh, Dong-Sup Lee
Breast cancer is the second most common cancer and the most frequent cancer in women worldwide. Recent improvements in early detection and effective adjuvant chemotherapies have improved the survival of breast cancer patients. Even with initial disease remission, one-third of all breast cancer patients will relapse with distant metastasis. Breast cancer metastasis is largely an incurable disease and the main cause of death among breast cancer patients. Cancer metastasis is comprised of complex processes that are usually not controllable by intervention of a single molecular target...
September 2017: Laboratory Animal Research
https://www.readbyqxmd.com/read/29045938/effectiveness-of-nivolumab-versus-docetaxel-as-second-line-treatment-in-non-small-cell-lung-cancer-patients-in-clinical-practice
#7
Pablo Calpe-Armero, Rafael Ferriols-Lisart, Francisco Ferriols-Lisart, Alejandro Pérez-Pitarch
AIMS: To evaluate the effectiveness of nivolumab as second-line treatment compared to standard therapy with docetaxel in adult patients with non-small cell lung cancer (NSCLC) in clinical practice. METHODS: This is an observational, retrospective cohort study of adult patients diagnosed with NSCLC, stage III-IV, treated with docetaxel or nivolumab as second-line treatment. The end points evaluated were overall survival (OS) and progression-free survival (PFS). PFS and OS were described using the Kaplan-Meier method...
October 19, 2017: Chemotherapy
https://www.readbyqxmd.com/read/29045843/high-throughput-functional-genetic-and-compound-screens-identify-targets-for-senescence-induction-in-cancer
#8
Liqin Wang, Rodrigo Leite de Oliveira, Cun Wang, João M Fernandes Neto, Sara Mainardi, Bastiaan Evers, Cor Lieftink, Ben Morris, Fleur Jochems, Lisa Willemsen, Roderick L Beijersbergen, René Bernards
Senescence is a proliferation arrest that can result from a variety of stresses. Cancer cells can also undergo senescence, but the stresses that provoke cancer cells to undergo senescence are unclear. Here, we use both functional genetic and compound screens in cancer cells harboring a reporter that is activated during senescence to find targets that induce senescence. We show that suppression of the SWI/SNF component SMARCB1 induces senescence in melanoma through strong activation of the MAP kinase pathway...
October 17, 2017: Cell Reports
https://www.readbyqxmd.com/read/29045553/randomized-controlled-trial-of-s-1-versus-docetaxel-in-patients-with-non-small-cell-lung-cancer-previously-treated-with-platinum-based-chemotherapy-east-asia-s-1-trial-in-lung-cancer
#9
H Nokihara, S Lu, T S K Mok, K Nakagawa, N Yamamoto, Y K Shi, L Zhang, R A Soo, J C Yang, S Sugawara, M Nishio, T Takahashi, K Goto, J Chang, M Maemondo, Y Ichinose, Y Cheng, W T Lim, S Morita, T Tamura
Background: Chemotherapy remains a viable option for the management of advanced non-small-cell lung cancer (NSCLC) despite recent advances in molecular targeted therapy and immunotherapy. We evaluated the efficacy of oral 5-fluorouracil-based S-1 as second- or third-line therapy compared with standard docetaxel therapy in patients with advanced NSCLC. Patients and methods: Patients with advanced NSCLC previously treated with ≥1 platinum-based therapy were randomized 1:1 to docetaxel (60 mg/m2 in Japan, 75mg/m2 at all other study sites; day 1 in a 3-week cycle) or S-1 (80-120 mg/day, depending on body surface area; days 1-28 in a 6-week cycle)...
September 29, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045535/select-2-a-phase-ii-double-blind-randomised-placebo-controlled-study-to-assess-the-efficacy-of-selumetinib-plus-docetaxel-as-a-second-line-treatment-for-patients-with-advanced-or-metastatic-non-small-cell-lung-cancer
#10
J C Soria, A Fülöp, C Maciel, J R Fischer, G Girotto, S Lago, E Smit, G Ostoros, W E E Eberhardt, P Lishkovska, S Lovick, G Mariani, A McKeown, E Kilgour, P Smith, K Bowen, A Kohlmann, D J Carlile, P A Jänne
Background: Combination of selumetinib plus docetaxel provided clinical benefit in a previous Phase II trial for patients with KRAS-mutant advanced non-small cell lung cancer (NSCLC). The Phase II SELECT-2 trial investigated safety and efficacy of selumetinib plus docetaxel for patients with advanced or metastatic NSCLC. Patients and methods: Patients who had disease progression after first-line anti-cancer therapy were randomised (2:2:1) to selumetinib 75 mg BID plus docetaxel 60 mg/m2 or 75 mg/m2 (SEL+DOC 60; SEL+DOC 75), or placebo plus docetaxel 75 mg/m2 (PBO+DOC 75)...
October 3, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/29045271/rhabdomyosarcoma-cells-are-susceptible-to-cell-death-by-ldk378-alone-or-in-combination-with-sorafenib-independently-of-anaplastic-lymphoma-kinase-status
#11
Nadezda Dolgikh, Simone Fulda
Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase that is often overexpressed in rhabdomyosarcoma (RMS). However, its oncogenic and functional role in RMS remains unclear. Therefore, we investigated the antitumor activity of LDK378 (ceritinib), a new second-generation ALK inhibitor approved for patients with ALK-positive non-small-cell lung cancers. Here, we report that LDK378 reduces cell viability and induces cell death in RMS cell lines at low micromolar IC50 concentrations irrespective of ALK expression levels or phosphorylation status...
November 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/29041833/healthcare-costs-in-patients-with-advanced-non-small-cell-lung-cancer-and-disease-progression-during-targeted-therapy-a-real-world-observational-study
#12
Karen E Skinner, Ancilla W Fernandes, Mark S Walker, Melissa Pavilack, Ari VanderWalde
AIMS: To assess healthcare costs during treatment with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and following disease progression in patients with advanced non-small cell lung cancer (NSCLC). METHODS: A retrospective analysis of medical records of US community oncology practices was conducted. Eligible patients had advanced NSCLC (stage IIIB/IV) diagnosed between January 1, 2008 and January 1, 2015, initiated treatment with erlotinib or afatinib (first-line or second-line), and had disease progression...
October 18, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/29037236/a-single-arm-phase-ii-study-of-nab-paclitaxel-for-patients-with-chemorefractory-non-small-cell-lung-cancer
#13
Hisashi Tanaka, Kageaki Taima, Takeshi Morimoto, Yoshihito Tanaka, Masamichi Itoga, Kunihiko Nakamura, Akihito Hayashi, Mika Kumagai, Hideo Yasugahira, Megumi Mikuniya, Koichi Okudera, Shingo Takanashi, Sadatomo Tasaka
BACKGROUND: We aimed to evaluate the efficacy and safety of nab-paclitaxel in patients with refractory advanced non-small cell lung cancer who failed previous chemotherapy. METHODS: Patients were required to have an Eastern Cooperative Oncology Group performance status of 0-2 and adequate organ function. Patients received nab-paclitaxel, 100 mg/m(2) i.v. on days 1, 8, and 15 every 4 weeks. The primary endpoint was the overall response rate. Secondary endpoints were the progression-free survival time, overall survival, and the toxicity profile...
October 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29034756/a-prediction-model-for-early-death-in-non-small-cell-lung-cancer-patients-following-curative-intent-chemoradiotherapy
#14
Arthur Jochems, Issam El-Naqa, Marc Kessler, Charles S Mayo, Shruti Jolly, Martha Matuszak, Corinne Faivre-Finn, Gareth Price, Lois Holloway, Shalini Vinod, Matthew Field, Mohamed Samir Barakat, David Thwaites, Dirk de Ruysscher, Andre Dekker, Philippe Lambin
BACKGROUND: Early death after a treatment can be seen as a therapeutic failure. Accurate prediction of patients at risk for early mortality is crucial to avoid unnecessary harm and reducing costs. The goal of our work is two-fold: first, to evaluate the performance of a previously published model for early death in our cohorts. Second, to develop a prognostic model for early death prediction following radiotherapy. MATERIAL AND METHODS: Patients with NSCLC treated with chemoradiotherapy or radiotherapy alone were included in this study...
October 14, 2017: Acta Oncologica
https://www.readbyqxmd.com/read/29034482/deep-reinforcement-learning-for-automated-radiation-adaptation-in-lung-cancer
#15
Huan-Hsin Tseng, Yi Luo, Sunan Cui, Jen-Tzung Chien, Randall K Ten Haken, Issam El Naqa
PURPOSE: To investigate deep reinforcement learning (DRL) based on historical treatment plans for developing automated radiation adaptation protocols for non-small cell lung cancer (NSCLC) patients that aim to maximize tumor local control at reduced rates of radiation pneumonitis grade 2 (RP2). METHODS: In a retrospective population of 114 NSCLC patients who received radiotherapy, a 3-component neural networks framework was developed for deep reinforcement learning (DRL) of dose fractionation adaptation...
October 16, 2017: Medical Physics
https://www.readbyqxmd.com/read/29032320/methodological-issues-of-assessing-the-risk-of-a-second-cancer-occurring-in-the-same-site-as-a-first-cancer-using-registry-data
#16
Jérémie Jégu, Marie Moitry, Simona Bara, Brigitte Trétarre, Anne-Valérie Guizard, Anne-Sophie Woronoff, Laetitia Daubisse-Marliac, Véronique Bouvier, Xavier Troussard, Marc Colonna, Delphine Klein, Bénédicte Lapôtre-Ledoux, Michel Velten
OBJECTIVE: To present methodological issues that can arise with the assessment of the risk of a second primary cancer (SPC) occurring in the same site as a first cancer using registry data. MATERIAL AND METHODS: Data from ten French cancer registries were used, including data for patients with a first prostate cancer (in males), breast cancer (in females), and colon, lung and kidney cancer (in both sexes) diagnosed between 1989 and 2004. Standardized incidence ratios (SIRs) of SPC were computed by excluding, or not, the risk of an SPC at the same site...
October 12, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/29032042/a-reliable-and-stable-method-for-determination-of-brigatinib-in-rat-plasma-by-uplc-ms-ms-application-to-a-pharmacokinetic-study
#17
Jian Wen, Susu Bao, Yaoyao Cai, Bowen Zhang, Rongrong Wang, Chenchen Wang, Guoxin Hu
Brigatinib is the second-generation anaplastic lymphoma kinase - inhibitor in non-small cell lung cancer and it can overcome the crizotinib-resistance. Chromatographic separation was carried out on an Acquity Ultra Performance Liquid Chromatography (UPLC) unit with a BEH C18 column (2.1mm×50mm, 1.7μm). The mobile phase was composed of acetonitrile and 0.1% formic acid in water. No endogenous interfering compounds was discovered at retention time of brigatinib (0.56min) and imatinib (IS, 1.41min). MS/MS detection was performed in positive mode...
October 5, 2017: Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences
https://www.readbyqxmd.com/read/29029530/which-treatment-is-preferred-for-advanced-non-small-cell-lung-cancer-with-wild-type-epidermal-growth-factor-receptor-in-second-line-therapy-a-meta-analysis-comparing-immune-checkpoint-inhibitor-tyrosine-kinase-inhibitor-and-chemotherapy
#18
Di Wu, Chongyang Duan, Fenfang Wu, Liyong Chen, Size Chen
BACKGROUND: The recommendations regarding the optimum treatment for advanced non-small-cell lung cancer (NSCLC) patients with wild-type (WT) epidermal growth factor receptor (EGFR) tumors remain unclear. This meta-analysis was conducted to assess the efficacy among programmed death-ligand 1 (PD-L1)/programmed death-1 (PD-1) antibody, EGFR-tyrosine kinase inhibitors (TKI) and chemotherapy in second-and third-line therapy. PATIENTS AND METHODS: Randomized trials investigating two of the three treatments were searched and included...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029508/efficiency-of-low-dosage-apatinib-in-post-first-line-treatment-of-advanced-lung-adenocarcinoma
#19
Da-Xiong Zeng, Chang-Guo Wang, Wei Lei, Jian-An Huang, Jun-Hong Jiang
Chemotherapy is the standard treatment of in advanced lung adenocarcinoma patients without driver mutation. However, few drugs could be selected when diseases progressed after second-line treatment. As a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2), apatinib was suggested mainly using in advanced gastric cancer. In this study, we showed the results of apatinib as second-line to fourth-line treatment in EGFR wild-type advanced lung adenocarcinoma patients. 16 EGFR wild-type advanced lung adenocarcinoma patients were administrated apatinib (250-500 mg/d) orally...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29026990/are-exon-19-deletions-and-l858r-different-in-early-stage-lung-adenocarcinoma
#20
Yiliang Zhang, Yuan Ma, Yuan Li, Xuxia Shen, Yongfu Yu, Yunjian Pan, Yang Zhang, Su Yu, Difan Zheng, Yue Zhao, Hong Hu, Yihua Sun, Yawei Zhang, Jiaqing Xiang, Haiquan Chen
INTRODUCTION: Evidence shows that exon 19 deletions (19del) and exon 21 Leu858Arg point mutation (L858R) of EGFR are different in response to EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy in advanced lung cancers. However, the impact of the two mutational types in the early stage lung adenocarcinoma is unknown. METHODS: We enrolled consecutive patients with operable adenocarcinoma which harbored 19del or L858R to investigate the clinicopathologic characteristics and prognostic outcomes...
October 12, 2017: Journal of Cancer Research and Clinical Oncology
keyword
keyword
89876
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"